These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://rajanuiex062597.gynoblog.com/37999680/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide